Observational studyCancer science2021
CD4
Observational study in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Biomarkers in oral squamous cell carcinoma: a systematic review.Medicina oral, patologia oral y cirugia bucal · 2026Pooled it
- Exploratory immunomonitoring during radiochemotherapy in HNSCC and machine-learning reveal immune parameters associated with disease-free survival.NPJ precision oncology · 2026Article
- Review
- Photodynamic priming with Vitamin D and ALA-based PDT induces intratumoral immune cell recruitment and signaling pathway activation in cutaneous squamous cell carcinoma.Cancer immunology, immunotherapy : CII · 2026Article
- Expression of intracellular toll-like receptors in leukoplakia and oral squamous cell carcinoma.Acta odontologica Scandinavica · 2026Article
- Photodynamic priming with Vitamin D and ALA-based PDT induces intratumoral immune cell recruitment and signaling pathway activation in murine cutaneous squamous cell carcinoma.bioRxiv : the preprint server for biology · 2026Article
- Targeting cellular source-specific CXCL9 signaling for immunotherapy in oral squamous cell carcinoma.Frontiers in immunology · 2026Review
- HLA-DR⁺ Tumor Cells Show an Association with a Distinct Immune Microenvironment and CD8⁺ T-Cell Exhaustion in HBV-Associated Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Differentiation of Cytotoxic CD8Cancer science · 2025Review
- In situ treatment with a TLR9 agonist virus-like particle to promote immune responses against oral epithelial dysplasia progression.Cancer immunology, immunotherapy : CII · 2025Article
- Review
- High expression of PD-L1 on conventional dendritic cells in tumour-draining lymph nodes is associated with poor prognosis in oral cancer.Cancer immunology, immunotherapy : CII · 2024Article
- Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods.Heliyon · 2024Review
- Prognostic value of T regulatory cells and immune checkpoints expression in tumor-draining lymph nodes for oral squamous cell carcinoma.Frontiers in immunology · 2024Article
- Enlarged tumour-draining lymph node with immune-activated profile predict favourable survival in non-metastatic colorectal cancer.British journal of cancer · 2024Article
- Intravenous injection of tumor extracellular vesicles suppresses tumor growth by reducing the regulatory T cell phenotype.Cancer immunology, immunotherapy : CII · 2023Article
- Article
- Piezo1 facilitates optimal T cell activation during tumor challenge.Oncoimmunology · 2023Article
- Immunology of Oral Squamous Cell Carcinoma-A Comprehensive Insight with Recent Concepts.Life (Basel, Switzerland) · 2022Review
- Pregnancy imparts distinct systemic adaptive immune function.American journal of reproductive immunology (New York, N.Y. : 1989) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Anticancer immunotherapies have revolutionized cancer management, yet the effect of systemic anti-programmed cell death protein 1 (PD-1) treatment is predominantly studied in tumor-infiltrating lymphocytes (TILs). Its impact on PD-1 expressing cells in tumor-draining lymph nodes (TDLNs) is not well understood and yet to be explored. Thus, further research aiming for better understanding of the PD-1 pathway not only in tumor tissue but also in TDLNs is warranted. In this study, we investigated the expression of PD-1, CD69, and HLA-DR on CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.